GlassScriptPhysician profile
Aimee A Todd
NPI 1720477961
$527.47
in general payments reported to CMS, 2019-2025
10 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $278 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $193.88 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.95 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $46.64 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.80 | 2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $37.06 | 2024 | Eliquis |
| Merck Sharp & Dohme LLC | $26.86 | 2024 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $25.18 | 2025 | |
| Novo Nordisk INC | $23.30 | 2024 | Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $20.89 | 2024 | Onpattro |
| Amgen INC. | $16.91 | 2024 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.